Dapagliflozin fares better than glipizide as add-on diabetes drug

07/21/2013 | InternalMedicineNews.com (free registration)

A Phase III study of 814 patients with type 2 diabetes indicated that 67% of those who used dapagliflozin as an add-on to metformin saw reductions in both weight and HbA1C levels at 52 weeks, compared with 21% of those who used glipizide as an add-on treatment. The findings were presented at the American Diabetes Association's 73rd Scientific Sessions.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN